Intec Pharma Ltd. (NASDAQ:NTEC) and Corcept Therapeutics Incorporated (NASDAQ:CORT) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||N/A||0.00||43.54M||-1.40||0.00|
|Corcept Therapeutics Incorporated||251.25M||5.63||75.41M||0.60||21.38|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 demonstrates the return on assets, return on equity and net margins of Intec Pharma Ltd. and Corcept Therapeutics Incorporated.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
|Corcept Therapeutics Incorporated||30.01%||30.3%||26.7%|
The table delivered features the ratings and recommendations for Intec Pharma Ltd. and Corcept Therapeutics Incorporated.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intec Pharma Ltd.||0||0||0||0.00|
|Corcept Therapeutics Incorporated||0||2||0||2.00|
Competitively Corcept Therapeutics Incorporated has a consensus target price of $13, with potential upside of 5.43%.
Insider & Institutional Ownership
Roughly 39.64% of Intec Pharma Ltd. shares are owned by institutional investors while 80.3% of Corcept Therapeutics Incorporated are owned by institutional investors. Insiders owned roughly 11.81% of Intec Pharma Ltd.’s shares. Comparatively, Corcept Therapeutics Incorporated has 2.8% of it’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||-5.95%||4.85%||37.69%||116.32%||34.75%||9.02%|
|Corcept Therapeutics Incorporated||10.88%||13.95%||-8.61%||-13.98%||-13.92%||-4.64%|
For the past year Intec Pharma Ltd. has 9.02% stronger performance while Corcept Therapeutics Incorporated has -4.64% weaker performance.
On 10 of the 11 factors Corcept Therapeutics Incorporated beats Intec Pharma Ltd.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with CushingÂ’s syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.